Filing Flows › Earth Science Tech (ETST) › Q1 FY27 › vs Q1 FY26
Earth Science Tech (ETST) Q1 FY27 vs Q1 FY26 (year over year)
Earth Science Tech's revenue rose $266K (+3%) from $8.8M in Q1 FY26 to $9.0M in Q1 FY27. The biggest changes: Sale of Pharmaceutical Products and Medical Consultations +$245K (+3%); Other Revenue +$21K (+192%). Gross margin 69.5% against 69.5% (-0.0 pts).
Earth Science Tech, Q1 FY27: revenue $9.0M (+3% year over year), operating margin 10.6%, net earnings $716K, operating cash flow $707K. The chart draws each line against Q1 FY26, the increases inside each band.
Margins
| Q1 FY27 | Q1 FY26 | Change | |
|---|---|---|---|
| Gross margin | 69.5% | 69.5% | -0.0 pts |
| Operating margin | 10.6% | 5.2% | +5.4 pts |
| Net margin | 7.9% | 5.2% | +2.7 pts |
| Free cash flow margin | 7.4% | 1.2% | +6.2 pts |
Every line
| Line | Q1 FY27 | Q1 FY26 | Change | % |
|---|---|---|---|---|
| Sale of Pharmaceutical Products and Medical Consultations | $9.0M | $8.7M | $245K | +3% |
| Other Revenue | $31K | $11K | $21K | +192% |
| Revenue | $9.0M | $8.8M | $266K | +3% |
| Gross profit | $6.3M | $6.1M | $184K | +3% |
| Cost of revenue | $2.8M | $2.7M | $81K | +3% |
| Operating profit | $958K | $457K | $502K | +110% |
| Operating expenses | $5.3M | $5.6M | −$317K | -6% |
| Pre-tax earnings | $958K | $457K | $502K | +110% |
| SG&A | $1.1M | $980K | $70K | +7% |
| Other operating costs | $4.3M | $4.7M | −$387K | -8% |
| Net earnings | $716K | $457K | $259K | +57% |
| Income tax | $243K | $0 | $243K | — |
| Depreciation & amortization | $67K | $39K | $28K | +73% |
| Working capital & other | $75K | $156K | −$80K | -52% |
| Operating cash flow | $707K | $339K | $368K | +108% |
| Free cash flow (OCF − capex) | $666K | $107K | $559K | +521% |
| Capital expenditures | $41K | $232K | −$191K | -82% |
Questions
How much did Earth Science Tech's revenue grow year over year in Q1 FY27?
Earth Science Tech's revenue rose $266K (+3%) from $8.8M in Q1 FY26 to $9.0M in Q1 FY27.
What drove Earth Science Tech's revenue change in Q1 FY27?
Sale of Pharmaceutical Products and Medical Consultations +$245K (+3%); Other Revenue +$21K (+192%).